| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 248.1 | 238.5 | 210.1 |
| Other income | 5.1 | 4.4 | 5.2 |
| Total income | 253.2 | 242.9 | 215.3 |
| Profit before exceptional items & tax | 22.9 | 20.2 | 23.3 |
| Profit before tax | 22.9 | 20.2 | 23.3 |
| Net profit | 17.7 | 16.0 | 17.7 |
| Operating margin | 9.0% | 8.3% | 10.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +0.00% |
|---|---|
| Net profit, quarter on quarter | +10.60% |
| Revenue, year on year | +18.10% |
| Operating profit, year on year | -1.70% |
| Operating profit, quarter on quarter | +12.70% |
BSE results filing, NSE: WINDLAS. Figures extracted from the filing.
Windlas Biotech Ltd: key numbers
- Share price
- ₹1,036.20
- Market cap
- ₹2,175 Cr
- Revenue (annual)
- ₹904.1 Cr
- Net profit (annual)
- ₹66.44 Cr
- P/E (TTM)
- 32.7×Sector 47.4×
- Promoter holding
- 63.31%+1.41% QoQ
- FII holding
- 2.04%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Windlas Biotech Ltd
All →Windlas Biotech Earnings Call Transcript: Key Takeaways
Windlas Biotech reported record quarterly revenue driven by 29% growth in CDMO vertical. Management focuses on operational excellence and capacity expansion via Plant 6 commercialization.
Windlas Biotech Results Update
Windlas Biotech reported Q1 FY27 revenue of Rs 248 crore, an 18% YoY growth. The release highlights an adjusted EBITDA of Rs 34 crore and PAT of Rs 25 crore.
Windlas Biotech Investor Presentation: Key Takeaways
Windlas Biotech reported Q1FY27 revenue of ₹248 Cr (18% YoY). Adjusted EBITDA and PAT grew 26% and 37% respectively, excluding ESOP costs, driven by CDMO expansion.
Windlas Biotech Board Meeting Date
Windlas Biotech Limited has scheduled a board meeting on August 10, 2026, to consider and approve its unaudited standalone financial results for the quarter ending June 30, 2026.
Windlas Biotech Annual General Meeting
Windlas Biotech Ltd held its 25th Annual General Meeting on July 23, 2026. Shareholders approved the financial statements and a final dividend of Rs. 6.30 per share.
Windlas Biotech Annual Report
Windlas Biotech Limited filed its Annual Report for the financial year 2025-26. The report highlights the company's operational performance and growth milestones.